Medical Developments International (MVP) investor relations material

Executive summary

• Achieved positive free cashflow for both Q4 and the full FY26 year, reflecting improved operational efficiency and margin enhancement.

• Penthrox revenue increased by $5.4 million year-over-year, with significant volume growth in both Australian and European markets.

• Regulatory approval and launch of Penthrox paediatric label in the UK and all EU member states, expanding the addressable market.

Financial highlights

• Group revenue for Q4 FY26 was $10.5 million, up $0.3 million from the prior corresponding period; full year revenue reached $42.6 million, up $3.5 million year-over-year.

• Pain Management segment revenue for the quarter was $7.9 million, up $0.4 million; full year revenue was $31.7 million, up $5.4 million.

• Respiratory segment revenue for the quarter was $2.6 million, down $0.1 million; full year revenue was $10.9 million, down $1.9 million.

• Cash generated from operating activities in Q4 was $3.0 million; full year operating cash flow was $5.8 million, both improved year-over-year.

• Cash balance at 30 June 2026 was $21.4 million.

Outlook and guidance

• FY26 EBIT is expected to be modestly improved over FY25, with full year results to be reported on 20 August 2026.

• Expansion of Penthrox's paediatric indication in Europe and the UK is anticipated to drive future growth.